Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma

Carmen Jerónimo, Henning Usadel, Rui Henrique, Jorge Oliveira, Carlos Lopes, William G Nelson, David Sidransky

Research output: Contribution to journalArticle

Abstract

Background: Methylation of regulatory sequences near GSTP1, which encodes the π class glutathione S-transferase, is the most common epigenetic alteration associated with prostate cancer. We determined whether the quantitation of GSTP1 methylation in histopathologically distinct prostate tissue samples could improve prostate cancer detection. Methods: We used a fluorogenic real-time methylation-specific polymerase chain reaction (MSP) assay to analyze cytidine methylation in the GSTP1 promoter in prostate tissue samples from 69 patients with early-stage prostatic adenocarcinoma (28 of whom also had prostatic intraepithelial neoplasia lesions) and 31 patients with benign prostatic hyperplasia. The relative level of methylated GSTP1 DNA in each sample was determined as the ratio of MSP-amplified GSTP1 to MYOD1, a reference gene. We also performed a prospective, blinded investigation to quantitate GSTP1 promoter methylation in sextant prostate biopsy specimens from 21 additional patients with elevated serum prostate-specific antigen levels, 11 of whom had histologically identified adenocarcinoma and 10 of whom had no morphologic evidence of adenocarcinoma. All data were analyzed by using nonparametric two-sided statistical tests. Results: The median ratios (and interquartile ranges) of MSP-amplified GSTP1 to MYOD1 in resected benign hyperplastic prostatic tissue, intraepithelial neoplasia, and adenocarcinoma were 0 (range, 0-0.1), 1.4 (range, 0-45.9), and 250.8 (range, 53.5-697.5), respectively; all of these values were statistically significantly different (P

Original languageEnglish (US)
Pages (from-to)1747-1752
Number of pages6
JournalJournal of the National Cancer Institute
Volume93
Issue number22
StatePublished - Nov 21 2001

Fingerprint

Methylation
Prostate
Adenocarcinoma
Prostatic Intraepithelial Neoplasia
Prostatic Neoplasms
Cytidine
Prostatic Hyperplasia
Prostate-Specific Antigen
Glutathione Transferase
Epigenomics
Biopsy
Polymerase Chain Reaction
DNA
Serum
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. / Jerónimo, Carmen; Usadel, Henning; Henrique, Rui; Oliveira, Jorge; Lopes, Carlos; Nelson, William G; Sidransky, David.

In: Journal of the National Cancer Institute, Vol. 93, No. 22, 21.11.2001, p. 1747-1752.

Research output: Contribution to journalArticle

Jerónimo, Carmen ; Usadel, Henning ; Henrique, Rui ; Oliveira, Jorge ; Lopes, Carlos ; Nelson, William G ; Sidransky, David. / Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. In: Journal of the National Cancer Institute. 2001 ; Vol. 93, No. 22. pp. 1747-1752.
@article{f88e3c4bbb6241bba80e8f0ec6a6f46a,
title = "Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma",
abstract = "Background: Methylation of regulatory sequences near GSTP1, which encodes the π class glutathione S-transferase, is the most common epigenetic alteration associated with prostate cancer. We determined whether the quantitation of GSTP1 methylation in histopathologically distinct prostate tissue samples could improve prostate cancer detection. Methods: We used a fluorogenic real-time methylation-specific polymerase chain reaction (MSP) assay to analyze cytidine methylation in the GSTP1 promoter in prostate tissue samples from 69 patients with early-stage prostatic adenocarcinoma (28 of whom also had prostatic intraepithelial neoplasia lesions) and 31 patients with benign prostatic hyperplasia. The relative level of methylated GSTP1 DNA in each sample was determined as the ratio of MSP-amplified GSTP1 to MYOD1, a reference gene. We also performed a prospective, blinded investigation to quantitate GSTP1 promoter methylation in sextant prostate biopsy specimens from 21 additional patients with elevated serum prostate-specific antigen levels, 11 of whom had histologically identified adenocarcinoma and 10 of whom had no morphologic evidence of adenocarcinoma. All data were analyzed by using nonparametric two-sided statistical tests. Results: The median ratios (and interquartile ranges) of MSP-amplified GSTP1 to MYOD1 in resected benign hyperplastic prostatic tissue, intraepithelial neoplasia, and adenocarcinoma were 0 (range, 0-0.1), 1.4 (range, 0-45.9), and 250.8 (range, 53.5-697.5), respectively; all of these values were statistically significantly different (P",
author = "Carmen Jer{\'o}nimo and Henning Usadel and Rui Henrique and Jorge Oliveira and Carlos Lopes and Nelson, {William G} and David Sidransky",
year = "2001",
month = "11",
day = "21",
language = "English (US)",
volume = "93",
pages = "1747--1752",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "22",

}

TY - JOUR

T1 - Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma

AU - Jerónimo, Carmen

AU - Usadel, Henning

AU - Henrique, Rui

AU - Oliveira, Jorge

AU - Lopes, Carlos

AU - Nelson, William G

AU - Sidransky, David

PY - 2001/11/21

Y1 - 2001/11/21

N2 - Background: Methylation of regulatory sequences near GSTP1, which encodes the π class glutathione S-transferase, is the most common epigenetic alteration associated with prostate cancer. We determined whether the quantitation of GSTP1 methylation in histopathologically distinct prostate tissue samples could improve prostate cancer detection. Methods: We used a fluorogenic real-time methylation-specific polymerase chain reaction (MSP) assay to analyze cytidine methylation in the GSTP1 promoter in prostate tissue samples from 69 patients with early-stage prostatic adenocarcinoma (28 of whom also had prostatic intraepithelial neoplasia lesions) and 31 patients with benign prostatic hyperplasia. The relative level of methylated GSTP1 DNA in each sample was determined as the ratio of MSP-amplified GSTP1 to MYOD1, a reference gene. We also performed a prospective, blinded investigation to quantitate GSTP1 promoter methylation in sextant prostate biopsy specimens from 21 additional patients with elevated serum prostate-specific antigen levels, 11 of whom had histologically identified adenocarcinoma and 10 of whom had no morphologic evidence of adenocarcinoma. All data were analyzed by using nonparametric two-sided statistical tests. Results: The median ratios (and interquartile ranges) of MSP-amplified GSTP1 to MYOD1 in resected benign hyperplastic prostatic tissue, intraepithelial neoplasia, and adenocarcinoma were 0 (range, 0-0.1), 1.4 (range, 0-45.9), and 250.8 (range, 53.5-697.5), respectively; all of these values were statistically significantly different (P

AB - Background: Methylation of regulatory sequences near GSTP1, which encodes the π class glutathione S-transferase, is the most common epigenetic alteration associated with prostate cancer. We determined whether the quantitation of GSTP1 methylation in histopathologically distinct prostate tissue samples could improve prostate cancer detection. Methods: We used a fluorogenic real-time methylation-specific polymerase chain reaction (MSP) assay to analyze cytidine methylation in the GSTP1 promoter in prostate tissue samples from 69 patients with early-stage prostatic adenocarcinoma (28 of whom also had prostatic intraepithelial neoplasia lesions) and 31 patients with benign prostatic hyperplasia. The relative level of methylated GSTP1 DNA in each sample was determined as the ratio of MSP-amplified GSTP1 to MYOD1, a reference gene. We also performed a prospective, blinded investigation to quantitate GSTP1 promoter methylation in sextant prostate biopsy specimens from 21 additional patients with elevated serum prostate-specific antigen levels, 11 of whom had histologically identified adenocarcinoma and 10 of whom had no morphologic evidence of adenocarcinoma. All data were analyzed by using nonparametric two-sided statistical tests. Results: The median ratios (and interquartile ranges) of MSP-amplified GSTP1 to MYOD1 in resected benign hyperplastic prostatic tissue, intraepithelial neoplasia, and adenocarcinoma were 0 (range, 0-0.1), 1.4 (range, 0-45.9), and 250.8 (range, 53.5-697.5), respectively; all of these values were statistically significantly different (P

UR - http://www.scopus.com/inward/record.url?scp=0035930097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035930097&partnerID=8YFLogxK

M3 - Article

C2 - 11717336

AN - SCOPUS:0035930097

VL - 93

SP - 1747

EP - 1752

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 22

ER -